Joined January 2021
- Tweets 35
- Following 138
- Followers 45
- Likes 43
7 Photos and videos
3 Mar 2023
A Personalised Clinical Dynamic Prediction Model to Characterise Prognosis for Patients with Localised Prostate Cancer: analysis of the CHHiP Phase III Trial redjournal.org/article/S0360…
1
1
173
Mark Brook retweeted
19 Dec 2022
Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study
buff.ly/3jcAERZ
@HolsUroLols @zx8754 @kotezsofi
1
6
21
9,350
Mark Brook retweeted
18 Jan 2022
Excited to see this work published! In a large sample of >22K African ancestry men, we show that a rare #HOXB13 variant found only in men of West African ancestry is associated with 2.4-fold higher risk of overall #prostatecancer and 5.1-fold higher risk of metastatic disease.
15 Jan 2022
A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry buff.ly/3I2YyGw
@BurcuDarst et al.
"HOXB13 X285K was associated with 2.4-fold increased odds of PCa (95% CI 1.5-3.9), with greater risk for more aggressive/advanced disease"
3
7
30
2 Feb 2022
"Risk of breast cancer in men in relation to weight change: a national case-control study in England and Wales"
Anthony Swerdlow, @CydneyLBruce, Rosie Cooke, Penny Coulson, @Minouk_Schoe, Michael Jones @AlchemiJones in IJC @intjcanc
onlinelibrary.wiley.com/doi/…
2
Mark Brook retweeted
19 Jan 2022
Very sad that Hon Fellow of @BritishAcademy_ Sir David Cox has died. He was a towering figure in the field of statistics. I remember getting him to do one of the @RoyalStatSoc 180th anniversary lectures in 2014 when he was 90 and still on fine form youtu.be/xRik3vOKLcU
3
124
276
Mark Brook retweeted
25 Jan 2022
Our manuscript on the evaluation of associations of BRCA1 and BRCA2 mutations with 22 different cancers (other than breast/ovarian cancers in women) out @JCO_ASCO. Analysed Data from >5000 families with mutations from CIMBA
@oncoalert #gcchat @CRUK_CI
ascopubs.org/doi/abs/10.1200…
1
14
27
Mark Brook retweeted
9 Nov 2021
Results of the first screening round of the IMPACT study for men with mismatch repair genes pathogenic variants.
Read more 👇
prostate.uroonco.uroweb.org/…
#prostatecancer #Movember
@marcobrooko @judeoffman @SapnaSyngal @roodvdb
4
4
20 Oct 2021
"A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study"
Elizabeth Bancroft @LizBancroft2, Elizabeth Page, Ros Eeles in @TheLancetOncol
thelancet.com/journals/lanon…
Mark Brook retweeted
20 Oct 2021
"Our new findings show that PSA testing in men with #LynchSyndrome is much more likely to pick up life-threatening #ProstateCancer than in the general population." - Professor Rosalind Eeles, of the ICR and @royalmarsdenNHS.
Read more in @BBCNews.
bbc.co.uk/news/health-589524…
11
19
Mark Brook retweeted
11 Oct 2021
The PROFILE study aims to understand why some men, including black men, are at greater risk of #ProstateCancer.
Winston, Richard, Frederick, and Olivier explain why more men should sign up 👇🏿👇🏼👇🏾
#BlackInCancerWeek21 @cancerBRC @royalmarsdenNHS @ProstateUK @realpaulparker2
14
25
Mark Brook retweeted
31 Aug 2021
📢 The ICR's and @royalmarsdenNHS' PACE-B trial showed that using advanced radiotherapy called SBRT to deliver precise treatment over a short time frame in #ProstateCancer, didn't lead to worse side effects compared to standard #Radiotherapy 👇
icr.ac.uk/news-archive/short…
3
11
Mark Brook retweeted
26 Jun 2021
An interesting tale of science communication, journalism and the culture wars has just dropped - 🧵
@JenniferRaff @ewanbirney @aylwyn_scally @minouye271 I recently published a paper about the lexicon of genetics, and how it needs to be addressed
bit.ly/3ddQu96
5
41
109
Mark Brook retweeted
23 Jun 2021
"Thanks to you, this study will help us understand more about the genetics of prostate cancer."
@realpaulparker2 is taking part in our groundbreaking PROFILE study to help us understand why black men are twice as likely to get prostate cancer.
Join him: bit.ly/2I4rJzt
7
28
Mark Brook retweeted
21 Jun 2021
A group of us (@minouye271, @JenniferRaff, @aylwyn_scally @AdamRutherford and myself) have written a piece on the language we use in genetics; untangling from previous sometimes racist language and being more precise and less harmful. We welcome feedback. arxiv.org/abs/2106.10041
5
54
129
Mark Brook retweeted
16 Jun 2021
Constructing and evaluating risk models in non-European ancestry populations is essential to broaden the impact of genomic medicine. Excited to be a part of this group @ChrisHaiman @johnwitte @GENES_PK and others supported by the consortium. @KECKSchool_USC @uscphs @USCBiostat
Research studies are starting to use polygenic risk scores to determine a person’s inherited risk for diseases. @NIH is awarding grants to develop methods that will improve how polygenic risk scores can be used to predict disease in diverse communities. bit.ly/3wednRj
2
8
24
Mark Brook retweeted
8 Jun 2021
Looking forward to Stephen Chanock talking on “Radiation, genomic alterations in papillary thyroid carcinoma and transgenerational studies following the Chernobyl accident” @mrc_ieu online seminar 21st June 3pm UK time, all welcome bristol.ac.uk/integrative-ep…
1
Mark Brook retweeted
11 May 2021
so excited to see this out. TWAS fails to implicate many risk regions as it focuses on steady-state expression levels. Enter CWAS, that uses chromatin variation to reveal context-dependent gene regulation as drivers of prostate cancer risk
biorxiv.org/content/10.1101/…
2
26
102
Mark Brook retweeted
29 May 2021
Really nice editorial on our recent @EUplatinum publication describing the combined effect of rare and common variants in #ProstateCancer. Discusses the use of RPMs/PRS/fam hx for screening and next steps needed to evaluate the clinical utility of #PRS
europeanurology.com/article/…
2
4
Mark Brook retweeted
28 May 2021
My thoughts on this piece, which lays out opportunities and challenges for improving cancer prevention and screening using polygenic risk models for cancer. I'm more optimistic than the authors. tl;dr Never say never; clinical utility is context-specific; more research needed.
Will polygenic risk scores (PRSs) for #cancer ever be #clinically useful?
Our (@clare__turnbull @HoulstonLab_ICR @ICR_London) commentary in @Nature_NPJ is out: nature.com/articles/s41698-0…
A thread:
1/n
1
33
74